PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search

Search

Reset

BNF Chapter

BNF Paragraph

Please select a BNF Chapter.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A to Z of Drugs : F

Records returned : 104 (on 17 May 2024 at 08:12:13).

Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
Factor VIIa (Recombinant)
No Information Returned
Factor VIII Inhibitor Bypass Fraction
No Information Returned
Factor XIII (Recombinant)
No Information Returned
Famciclovir
No Information Returned
Famotidine
No Information Returned
10.02.01
Fampridine
Multiple sclerosis
Red
Formulations :
  • Modified release tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
Specialist centre only
10.01.04
Febuxostat
Hyperuricaemia and Gout
Green
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
NICE
Important
For patients where allopurinol is not tolerated or contraindicated
04.08.01
Felbamate
Epilepsy
Red
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
U
10.03.02
Felbinac
Osteoarthritis
Non Formulary
Formulations :
  • Gel
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NFD1
Felodipine
No Information Returned
Fenbufen
No Information Returned
Fenofibrate
No Information Returned
Fenofibrate/simvastatin
No Information Returned
Fenoprofen
No Information Returned
Fenoterol hydrobromide
No Information Returned
04.07.02
Fentanyl
Pain
Red
Formulations :
  • Injection
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
CD
Important
See separate listing for use in assisted ventilation and anaesthesia
04.07.02
Fentanyl
Pain
Red
Formulations :
  • Injection
  • Nasal spray
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
CD
Un
Important
100mcg in 2ml injection used intranasally in paediatrics for painful procedures.
04.07.02
Fentanyl
Pain
Non Formulary
Formulations :
  • Buccal tablets
  • Buccal/sublingual
  • Nasal spray
  • Sublingual tablets
  • Lozenges
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
CD
Important
Immediate release fentanyl preparations are non-formulary for all pain indications EXCEPT for breakthrough pain in patients receiving opioid therapy for cancer pain.
Fentanyl citrate
No Information Returned
Fenticonazole nitrate
No Information Returned
Ferric chloride
No Information Returned
Ferric maltol
No Information Returned
Ferrous calcium citrate
No Information Returned
Ferrous fumarate
No Information Returned
Ferrous gluconate
No Information Returned
Ferrous glycine sulfate
No Information Returned
Ferrous sulfate
No Information Returned
Ferumoxytol
No Information Returned
07.04.02
Fesoterodine fumarate
Overactive bladder (adults)
Green (see narrative)
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
3rd line - for patients requiring more potent treatment
Fexofenadine hydrochloride
No Information Returned
05.01.07
Fidaxomicin
Clostridioides difficile
Green
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Granules (for oral suspension) should be used in patients requiring a liquid preparation.
01.05.03
10.01.03
Filgotinib
Ulcerative colitis
Red
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
01.05.03
10.01.03
Filgotinib
Rheumatoid arthritis
Red
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
SA
ICB
BlueTeq
NICE
Filgrastim
No Information Returned
06.04.02
Finasteride
Transgender Health - adults
Amber
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Un
08.02.04
Fingolimod
Multiple sclerosis
Red
Formulations :
  • Capsules
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
NHSE
BlueTeq
NICE
07.04.02
Flavoxate hydrochloride
Overactive bladder (adults)
Non Formulary
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
Flecainide acetate
No Information Returned
Flubiprofen
No Information Returned
Flucloxacillin magnesium
No Information Returned
Flucloxacillin sodium
No Information Returned
Fluconazole
No Information Returned
Fludarabine phosphate
No Information Returned
Fludrocortisone acetate
No Information Returned
Fludroxycortide
No Information Returned
Flumazenil
No Information Returned
Flumetasone pivalate
No Information Returned
04.06.00
04.07.04
Flunarizine dihydrochloride
Migraine (prevention)
Red
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
R
U
Important
Restricted to use in patients who are intolerant or refractory to other treatment options
Flunisolide
No Information Returned
Flunitrazepam
No Information Returned
11.04.01
13.04.00
Fluocinolone acetonide
Uveitis
Red
Formulations :
  • Intravitreal implant
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
Important
Ophthalmology specialists only.
11.04.01
13.04.00
Fluocinolone acetonide
Diabetic macular oedema
Red
Formulations :
  • Intravitreal implant
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
R
ICB
BlueTeq
NICE
Important
Ophthalmology specialists only. In patients who have failed to respond to prior treatments and have an intraocular lens.
Fluocinonide
No Information Returned
Fluocortolone
No Information Returned
Fluorescein sodium
No Information Returned
Fluorometholone
No Information Returned
Fluorouracil (Antimetabolites)
No Information Returned
Fluorouracil (Sunscreen)
No Information Returned
Fluoxetine hydrochloride
No Information Returned
Flupentixol decanoate
No Information Returned
Flupentixol hydrochloride
No Information Returned
Fluphenazine decanoate
No Information Returned
Fluphenazine hydrochloride
No Information Returned
Fluprednidene acetate
No Information Returned
Flurazepam hydrochloride
No Information Returned
Flurbiprofen
No Information Returned
Flurbiprofen sodium
No Information Returned
Flutamide
No Information Returned
Fluticasone furoate
No Information Returned
Fluticasone furoate (Inhalation)
No Information Returned
Fluticasone propionate (Inhalation)
No Information Returned
Fluticasone propionate (Nasal)
No Information Returned
Fluticasone propionate (Topical)
No Information Returned
Fluticasone propionate/azelastine hydrochloride (Nasal)
No Information Returned
Flutrimazole
No Information Returned
Fluvastatin sodium
No Information Returned
Fluvoxamine maleate
No Information Returned
Folic acid
No Information Returned
Follitropin alfa
No Information Returned
Follitropin alfa and lutropin alfa
No Information Returned
Follitropin beta
No Information Returned
Follitropin delta
No Information Returned
Fondaparinux sodium
No Information Returned
09.06.07
Forceval
post Bariatric surgery
Green (see narrative)
Formulations :
  • Capsules
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
ONLY after single anastomosis duodenal illeal bypass with sleeve (SADI-S) or duodenal switch surgery
Formaldehyde
No Information Returned
Formoterol fumarate
No Information Returned
Formoterol/glycopyrronium/budesonide
No Information Returned
Fosamprenavir calcium
No Information Returned
Fosaprepitant
No Information Returned
Foscarnet sodium
No Information Returned
Fosfestrol tetrasodium
No Information Returned
Fosfomycin calcium
No Information Returned
Fosfomycin trometamol
No Information Returned
Fosinopril sodium
No Information Returned
Fosphenytoin sodium
No Information Returned
Fostemsavir
No Information Returned
Framycetin sulfate
No Information Returned
Freeze sprays and gels
No Information Returned
04.07.04
Fremanezumab
Migraine (prevention)
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
04.07.04
Frovatriptan
Migraine (acute)
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Not 1st line. Generic sumatriptan, naratriptan, rizatripan, zolmitriptan are preferred.
04.07.04
Frovatriptan
Menstrual related migraine
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Un
Important
Off-label. Use if inadequate response to standard acute migraine treatments
Fructose
No Information Returned
Fuller's earth
No Information Returned
Fulvestrant
No Information Returned
Fumaric acid
No Information Returned
Furosemide
No Information Returned
Furosemide/potassium
No Information Returned
Fusafungine
No Information Returned
Fusidic acid
No Information Returned
 

For information about the icons and status values within this site, please refer to the keys below.

Icon/Links Key

NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq
BlueTeq form to be completed
NICE
NICE

Traffic Light Status Key

Red
Specialist ONLY drugs - treatment initiated and continued by specialist clinicians
Amber
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement
Green
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.
Black
Now referred to as "Non Formulary" but some BLACK drugs remain pending review. Not recommended for use in any health setting across Surrey and NW Sussex health economy.
Amber Star
Now referred to as "Blue" but some Amber Star drugs remain pending review. Prescribing initiated and stabliised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green (see narrative)
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.
Non Formulary
Not recommended for use in any health setting across Surrey and NW Sussex health economy. (Formerly BLACK traffic light status)
See Below
Please add a description.
N/A
Please add a description.
Blue
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green - Black
Now referred to as "Do not initiate in new patients" but some GREEN/BLACK drugs remain pending review. These drugs are NOT for new initiations (BLACK, (now referred to as Non Formulary)) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required.
See narrative
See narrative - is applied in instances where there may be more than one traffic light status for a drug. This occurs when the traffic light status may differ between specific cohorts of patients e.g. those of childbearing potential and those who are not (in the case of sodium valproate)
Do not initiate in new patients
These drugs are NOT for new initiations (Non Formulary) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required. (Formerly GREEN/BLACK traffic light status)
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More